Use of Biosimilar Medications in Oncology.

{"article_title":"Use of Biosimilar Medications in Oncology.","author":"Nahleh, Zeina , Lyman, Gary H , Schilsky, Richard L , Peterson, Douglas E , Tagawa, Scott T , Chavez-MacGregor, Mariana , Rumble, R Bryan , Gupta, Shilpi","journal_title":"JCO oncology practice","issn":"2688-1535 ; Electronic","isbn":"","publication_date":"20220301","volume":"18","issue":"3","first_page":"177","page_count":"10","accession_number":"35041524","doi":"10.1200\/OP.21.00771","publisher":"American Society of Clinical Oncology","doctype":"Journal Article; Review","subjects":"Oncoloy ","interest_area":["Oncology"],"abstract":"<b>Gary H. Lyman<\/b><b>Consulting or Advisory Role:<\/b> G1 Therapeutics, Samsung Bioepis, BeyondSpring Pharmaceuticals, Sandoz, Jazz Pharmaceuticals, Partner Therapeutics, E.R. Squibb Sons, LLC, MSD, Seattle Genetics, Kallyope, TEVA, Spectrum Pharmaceuticals, Frensenius Kabi <b>Research Funding:<\/b> Amgen (Inst) <b>Richard L. Schilsky<\/b><b>Leadership:<\/b> Clarified Precision Medicine <b>Consulting or Advisory Role:<\/b> Cellworks, Scandion Oncology, Bryologyx, Illumina, EQRx <b>Research Funding:<\/b> AstraZeneca (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Genentech\/Roche (Inst), Lilly (Inst), Merck (Inst), Pfizer (Inst), Boehringer Ingelheim (Inst), Seattle Genetics (Inst) <b>Open Payments Link:<\/b> https:\/\/openpaymentsdata.cms.gov\/physician\/1138818\/summary <b>Douglas E. Peterson<\/b><b>Stock and Other Ownership Interests:<\/b> Allergan (I), Celgene (I), Gilead Sciences (I), Procter & Gamble (I), Roche (I), Bristol Myers Squibb (I), Johnson & Johnson (I) <b>Honoraria:<\/b> PierianDx <b>Consulting or Advisory Role:<\/b> Amgen, PSI Pharma Support America, Applied Glycan-Oral Health, AEC Partners, BrainCool, Medicxi Ventures (UK) LLP, Boston MedTech Advisors <b>Scott T. Tagawa<\/b><b>Consulting or Advisory Role:<\/b> Medivation, Astellas Pharma, Dendreon, Janssen, Genentech, Endocyte, Immunomedics, Karyopharm Therapeutics, AbbVie, Tolmar, QED Therapeutics, Amgen, Sanofi, Pfizer, Clovis Oncology, Novartis, Genomic Health, POINT Biopharma, Blue Earth Diagnostics, Seattle Genetics, AIkido Pharma, 4D Pharma, Clarity Pharmaceuticals, Gilead Sciences, Telix Pharmaceuticals, Bayer, Myovant Sciences, Convergent Therapeutics <b>Research Funding:<\/b> Lilly (Inst), Sanofi (Inst), Janssen (Inst), Astellas Pharma (Inst), Progenics (Inst), Millennium (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), Dendreon (Inst), Rexahn Pharmaceuticals (Inst), Bayer (Inst), Genentech (Inst), Newlink Genetics (Inst), Inovio Pharmaceuticals (Inst), AstraZeneca (Inst), Immunomedics (Inst), Novartis (Inst), AVEO (Inst), Boehringer Ingelheim (Inst), Merck (Inst), Stem CentRx (Inst), Karyopharm Therapeutics (Inst), AbbVie (Inst), Medivation (Inst), Endocyte (Inst), Exelixis (Inst), Clovis Oncology (Inst), POINT Biopharma (Inst) <b>Patents, Royalties, Other Intellectual Property:<\/b> Patent Royalty from Immunomedics\/Gilead <b>Travel, Accommodations, Expenses:<\/b> Sanofi, Immunomedics, Amgen <b>Uncompensated Relationships:<\/b> ATLAB Pharma, Phosplatin Therapeutics <b>Mariana Chavez-MacGregor<\/b><b>Employment:<\/b> MD Anderson Physicians Network <b>Honoraria:<\/b> Pfizer, Eisai <b>Consulting or Advisory Role:<\/b> Roche\/Genentech, AstraZeneca, Novartis, Pfizer, asofar, Genomic Health, Exact Sciences, AstraZeneca\/Daiichi Sankyo <b>Research Funding:<\/b> Novartis (Inst) <b>Expert Testimony:<\/b> Abbott Laboratories, Pfizer <b>Travel, Accommodations, Expenses:<\/b> Pfizer <b>Other Relationship:<\/b> Roche <b>Uncompensated Relationships:<\/b> Legacy Healthcare Services, The Hope FoundationNo other potential conflicts of interest were reported.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=35041524&authtype=shib&custid=ns346513"}